Cargando…
Repurposing Butenafine as An Oral Nanomedicine for Visceral Leishmaniasis
Leishmaniasis is a neglected tropical disease affecting more than 12 million people worldwide, which in its visceral clinical form (VL) is characterised by the accumulation of parasites in the liver and spleen, and can lead to death if not treated. Available treatments are not well tolerated due to...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6680852/ https://www.ncbi.nlm.nih.gov/pubmed/31330776 http://dx.doi.org/10.3390/pharmaceutics11070353 |
_version_ | 1783441596560179200 |
---|---|
author | Bezerra-Souza, Adriana Fernandez-Garcia, Raquel Rodrigues, Gabriela F. Bolas-Fernandez, Francisco Dalastra Laurenti, Marcia Passero, Luiz Felipe Lalatsa, Aikaterini Serrano, Dolores R. |
author_facet | Bezerra-Souza, Adriana Fernandez-Garcia, Raquel Rodrigues, Gabriela F. Bolas-Fernandez, Francisco Dalastra Laurenti, Marcia Passero, Luiz Felipe Lalatsa, Aikaterini Serrano, Dolores R. |
author_sort | Bezerra-Souza, Adriana |
collection | PubMed |
description | Leishmaniasis is a neglected tropical disease affecting more than 12 million people worldwide, which in its visceral clinical form (VL) is characterised by the accumulation of parasites in the liver and spleen, and can lead to death if not treated. Available treatments are not well tolerated due to severe adverse effects, need for parenteral administration and patient hospitalisation, and long duration of expensive treatments. These treatment realities justify the search for new effective drugs, repurposing existing licensed drugs towards safer and non-invasive cost-effective medicines for VL. In this work, we provide proof of concept studies of butenafine and butenafine self-nanoemulsifying drug delivery systems (B-SNEDDS) against Leishmania infantum. Liquid B-SNEDDS were optimised using design of experiments, and then were spray-dried onto porous colloidal silica carriers to produce solid-B-SNEDDS with enhanced flow properties and drug stability. Optimal liquid B-SNEDDS consisted of Butenafine:Capryol 90:Peceol:Labrasol (3:49.5:24.2:23.3 w/w), which were then sprayed-dried with Aerosil 200 with a final 1:2 (Aerosil:liquid B-SNEDDS w/w) ratio. Spray-dried particles exhibited near-maximal drug loading, while maintaining excellent powder flow properties (angle of repose <10°) and sustained release in acidic gastrointestinal media. Solid-B-SNEDDS demonstrated greater selectivity index against promastigotes and L. infantum-infected amastigotes than butenafine alone. Developed oral solid nanomedicines enable the non-invasive and safe administration of butenafine as a cost-effective and readily scalable repurposed medicine for VL. |
format | Online Article Text |
id | pubmed-6680852 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-66808522019-08-09 Repurposing Butenafine as An Oral Nanomedicine for Visceral Leishmaniasis Bezerra-Souza, Adriana Fernandez-Garcia, Raquel Rodrigues, Gabriela F. Bolas-Fernandez, Francisco Dalastra Laurenti, Marcia Passero, Luiz Felipe Lalatsa, Aikaterini Serrano, Dolores R. Pharmaceutics Article Leishmaniasis is a neglected tropical disease affecting more than 12 million people worldwide, which in its visceral clinical form (VL) is characterised by the accumulation of parasites in the liver and spleen, and can lead to death if not treated. Available treatments are not well tolerated due to severe adverse effects, need for parenteral administration and patient hospitalisation, and long duration of expensive treatments. These treatment realities justify the search for new effective drugs, repurposing existing licensed drugs towards safer and non-invasive cost-effective medicines for VL. In this work, we provide proof of concept studies of butenafine and butenafine self-nanoemulsifying drug delivery systems (B-SNEDDS) against Leishmania infantum. Liquid B-SNEDDS were optimised using design of experiments, and then were spray-dried onto porous colloidal silica carriers to produce solid-B-SNEDDS with enhanced flow properties and drug stability. Optimal liquid B-SNEDDS consisted of Butenafine:Capryol 90:Peceol:Labrasol (3:49.5:24.2:23.3 w/w), which were then sprayed-dried with Aerosil 200 with a final 1:2 (Aerosil:liquid B-SNEDDS w/w) ratio. Spray-dried particles exhibited near-maximal drug loading, while maintaining excellent powder flow properties (angle of repose <10°) and sustained release in acidic gastrointestinal media. Solid-B-SNEDDS demonstrated greater selectivity index against promastigotes and L. infantum-infected amastigotes than butenafine alone. Developed oral solid nanomedicines enable the non-invasive and safe administration of butenafine as a cost-effective and readily scalable repurposed medicine for VL. MDPI 2019-07-20 /pmc/articles/PMC6680852/ /pubmed/31330776 http://dx.doi.org/10.3390/pharmaceutics11070353 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Bezerra-Souza, Adriana Fernandez-Garcia, Raquel Rodrigues, Gabriela F. Bolas-Fernandez, Francisco Dalastra Laurenti, Marcia Passero, Luiz Felipe Lalatsa, Aikaterini Serrano, Dolores R. Repurposing Butenafine as An Oral Nanomedicine for Visceral Leishmaniasis |
title | Repurposing Butenafine as An Oral Nanomedicine for Visceral Leishmaniasis |
title_full | Repurposing Butenafine as An Oral Nanomedicine for Visceral Leishmaniasis |
title_fullStr | Repurposing Butenafine as An Oral Nanomedicine for Visceral Leishmaniasis |
title_full_unstemmed | Repurposing Butenafine as An Oral Nanomedicine for Visceral Leishmaniasis |
title_short | Repurposing Butenafine as An Oral Nanomedicine for Visceral Leishmaniasis |
title_sort | repurposing butenafine as an oral nanomedicine for visceral leishmaniasis |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6680852/ https://www.ncbi.nlm.nih.gov/pubmed/31330776 http://dx.doi.org/10.3390/pharmaceutics11070353 |
work_keys_str_mv | AT bezerrasouzaadriana repurposingbutenafineasanoralnanomedicineforvisceralleishmaniasis AT fernandezgarciaraquel repurposingbutenafineasanoralnanomedicineforvisceralleishmaniasis AT rodriguesgabrielaf repurposingbutenafineasanoralnanomedicineforvisceralleishmaniasis AT bolasfernandezfrancisco repurposingbutenafineasanoralnanomedicineforvisceralleishmaniasis AT dalastralaurentimarcia repurposingbutenafineasanoralnanomedicineforvisceralleishmaniasis AT passeroluizfelipe repurposingbutenafineasanoralnanomedicineforvisceralleishmaniasis AT lalatsaaikaterini repurposingbutenafineasanoralnanomedicineforvisceralleishmaniasis AT serranodoloresr repurposingbutenafineasanoralnanomedicineforvisceralleishmaniasis |